422
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Real-life experience with ixekizumab in plaque psoriasis: a multi-center, retrospective, 3-year study

ORCID Icon, ORCID Icon, ORCID Icon, , , , , , ORCID Icon, ORCID Icon, , ORCID Icon, , ORCID Icon & show all
Pages 365-370 | Received 24 Nov 2022, Accepted 16 Mar 2023, Published online: 20 Mar 2023

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Massimo Travaglini, Julia-Tatjana Maul, Christian Kors, Shirin Zaheri, Jens Gerwien, Michaela Müller, Alan Brnabic, Silvia Sabatino, Christopher Schuster & Tsen-Fang Tsai. (2023) Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO). Clinical, Cosmetic and Investigational Dermatology 16, pages 2971-2983.
Read now
Andrea Chiricozzi, Matteo Megna, Alessandro Giunta, Carlo Giovanni Carrera, Paolo Dapavo, Anna Balato, Piergiorgio Malagoli, Stella Mazzoccoli, Aurora Parodi, Silvia Sabatino, Carlotta Buzzoni, Chu-Han Huang & Alessandra Narcisi. (2023) Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study). Journal of Dermatological Treatment 34:1.
Read now

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.